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Abstract
Background: Wharton’s jelly derived stem cells (WJMSCs) are gaining attention as a possible clinical alternative to bone
marrow derived mesenchymal stem cells (BMMSCs) owing to better accessibility, higher expansion potential and low
immunogenicity. Usage of allogenic mesenchymal stem cells (MSC) could be permissible in vivo only if they retain their
immune properties in an inflammatory setting. Thus the focus of this study is to understand and compare the immune
properties of BMMSCs and WJMSCs primed with key pro-inflammatory cytokines, Interferon-c (IFNc) and Tumor Necrosis
Factor-a (TNFa).
Methodology/Principal Findings: Initially the effect of priming on MSC mediated suppression of alloantigen and mitogen
induced lymphoproliferation was evaluated in vitro. Treatment with IFNc or TNFa, did not ablate the immune-suppression
caused by both the MSCs. Extent of immune-suppression was more with WJMSCs than BMMSCs in both the cases.
Surprisingly, priming BMMSCs enhanced suppression of mitogen driven lymphoproliferation only; whereas IFNc primed
WJMSCs were better suppressors of MLRs. Further, kinetic analysis of cytokine profiles in co-cultures of primed/unprimed
MSCs and Phytohematoagglutinin (PHA) activated lymphocytes was evaluated. Results indicated a decrease in levels of pro-
inflammatory cytokines. Interestingly, a change in kinetics and thresholds of Interleukin-2 (IL-2) secretion was observed only
with BMMSCs. Analysis of activation markers on PHA-stimulated lymphocytes indicated different expression patterns in co-
cultures of primed/unprimed WJMSCs and BMMSCs. Strikingly, co-culture with WJMSCs resulted in an early activation of a
negative co-stimulatory molecule, CTLA4, which was not evident with BMMSCs. A screen for immune suppressive factors in
primed/unprimed WJMSCs and BMMSCs indicated inherent differences in IFNc inducible Indoleamine 2, 3-dioxygenase
(IDO) activity, Hepatocyte growth factor (HGF) and Prostaglandin E-2 (PGE2) levels which could possibly influence the
mechanism of immune-modulation.
Conclusion/Significance: This study demonstrates that inflammation affects the immune properties of MSCs distinctly.
Importantly different tissue derived MSCs could utilize unique mechanisms of immune-modulation.
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Introduction
MSCs are plastic adherent cells expressing the minimal marker
set of CD90, CD73 and CD105 and absence of CD14, CD79,
CD34, CD45, and HLA-DR [1,2]. MSCs home to injured sites and
result in tissue regeneration in different injury models [3,4]. These
attributes of MSCs make them lucrative candidates for a cell based
regenerative and repair therapy. Usage of MSCs as cell based
therapeutics for repair is strengthened by the fact that MSCs appear
to escape immune surveillance [5]. Human MSCs can be probably
transplanted even against xenogenic barriers [6]. Bone marrow
derived MSCs have been shown to modify or attenuate the effector
functions of different immune populations like T cells, B cells,
natural killer (NK) cells and dendritic cells (DC) subsets [7–13].
Owing to their property of immune-modulation, MSCs are being
considered as double edged sword which can not only bring about
tissue repairbut also attenuate adverse inflammatory reactions inan
allogenic setting. The immune-modulatory actions of MSCs have
been tested in vivo. BMMSCs either reverse or prolong survival of
mismatched grafts and decrease GVHD [14–18]. Despite these
reports there are still contradictions in the literature on the immune
status of MSCs. Studies by Elippoulous et al., 2005 indicate that
allogenic murine MSCs result in robust cell mediated immune
responses in MHC class I and class II mismatched immuno-
competent mice [19]. It is still not clear whether MSCs cause
systemic immune suppression in vivo [20]. These discrepancies can
be explained only when we understand the local environmental
influences on immune behavior of MSCs.
MSCs have been identified and propagated from many different
tissue sources [21–23]. Most of the tissue derived stem cells have
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expression, differentiation into mesenchymal lineages and immune
suppressive behavior [24–27]. Despite commonalities amongst
stem cells isolated from diverse sources, tissue specific influences
on their stem cell behavior and immune properties cannot be
negated. Of particular interest are fetal MSCs which are more
primitive than the other tissue derived MSCs. MSCs derived from
the Wharton’s jelly or umbilical cord matrix is being considered as
a potential alternative to bone marrow because of ease of isolation,
higher expansion potential and greater accessibility of clinical
samples than BMMSCs. Moreover bone marrow isolation is a
painful and invasive procedure. Donor age differences have been
shown to influence proliferative characteristics and differentiation
capacity of BMMSCs [28]. Age related differences if any are
minimal in WJMSCs samples as compared to other MSCs.
WJMSCs are also immunosuppressive in in vitro lymphoprolifer-
ation experiments [29]. Human WJMSCs aided in neuronal
regeneration in a rat model of spinal cord injury [30]. However,
few reports suggest that not all fetal tissue derived MSCs have
robust immune suppression properties as observed in adult stem
cells [31,32]. Thus it is important to have an in depth insight of the
immunomodulatory behavior of MSCs derived from different
sources differing in their primitiveness.
MSCs are stated to be hypo-immunogenic; however they do
respond to inflammation. Inflammatory situation prevails during any
tissue injury and MSCs would be exposed to such stimuli in many
clinical conditions. The immune behavior of MSCs can be influenced
not only by neighboring cells but also environmental factors like
systemic or local inflammation as in case of Graft versus host disease
(GVHD). Few recent reports in fact indicate the role of inflammatory
cytokines in effecting immune functions of MSCs. IFNc has been
reported to enhance the immune-suppressive behavior of MSCs by
upregulation of inhibitory molecule B7-H1 [33]. IFNc induced
IDO production by MSCs was shown to be the key player in
immuno-suppression of T cells [34]. In comparison to wild type
MSCs, murine MSCs from IFNcR1
2/2 mice could not prevent
GVHD [35]. In contrast, in a collagen induced mouse model of
arthritis, MSCs did not cause beneficial effect in fact the report
proved that TNFa secreted at the inflammatory site could cause
reversal of immune-suppressive behavior [36]. IFNc and TNFa are
key pro-inflammatory cytokines mediating inflammatory events
during several injury and pathological situations. MSCs would be
exposed to these stimuli in an in vivo inflammation/transplantation
scenario. We have thus attempted to re-evaluate the immune
properties of MSCs from bone marrow and Wharton’s jelly when
primed with inflammatory stimuli, IFNc and TNFa The results
discussed in the paper highlight that although most MSCs from
different tissue sources are reported to be immune suppressive, they
adopt unique mechanisms for immune-modulation possibly due to
inherent differences in immune-suppressive factors expressed.
Further the study proposes that different inflammatory factors
modulate the immune-regulatory capacity of MSCs distinctly.
Materials and Methods
Antibodies
Anti human -MsCD73 PE, -MsCD90 PE, -MsCD105 PE,
-MsCD166 PE, -MsCD34 PE, -MsCD45 FITC, -MsCD19 PE,
-MsHLA-DR FITC, -MsHLA-ABC FITC, -MsCTLA4-FITC,
-MsCD50 FITC, -MsCD54 PE, -MsCD80 FITC, -MsCD86 PE,
-MsCD95 FITC, the relevant isotype controls, purified anti-
human -MsCD28, -MsCD69, -MsCD45RA, and -MsCD45RO
were obtained from BD Pharmingen, San Jose, CA,USA. Anti
human -goat FABP4, anti human -Ms Osteocalcin and -Ms
Collagen II were obtained from R&D SYSTEMS, Inc. Purified
anti human -MsSSEA4, rabbit anti-mouse IgG1 FITC and rabbit
anti-goat IgG1 FITC secondary antibodies used to detect the
primary antibodies were from Chemicon, Temecula, CA, USA.
Culture of Human Bone Marrow Derived MSCs
Bone marrow aspirates were drawn from iliac crest of donors
from Manipal hospital, Bangalore, India. Informed written
consent was obtained using an Institutional Review Board
approved protocol (Protocol No: MHB/SCR/010) from Ethics
committee of Manipal Hospital and Manipal Heart Foundation,
Bangalore, India. Bone marrow samples were diluted and layered
on Lymphoprep
TM (1.077 g/ml) obtained from Axis-shield PoC
AS (Norway) following which the sample was spun at 400 g for
20 minutes at 22uC. The buffy coat containing the mononuclear
cells was washed with Dulbecco’s phosphate buffered saline
(DPBS) from GIBCO-BRL, USA and plated in KO-DMEM
(GIBCO-BRL,USA) containing 10% FBS (HyClone, Utah, USA),
2 mM L-Glutamine (GIBCO-BRL,USA) and antibiotic-anti-
mycotic (GIBCO-BRL,USA). The adherent cells were propa-
gated in the above mentioned media in a humidified incubator
maintained at 37uC with 5% CO2. The initial plating densities and
seeding densities for propagation was as previously described
[37,38]. Bone marrow derived cells were characterized for the
presence of mesenchymal markers (CD73, CD44, CD90, CD105)
and absence of CD34 and CD45 before performing different
experiments (Figure S1A). All experiments were set up within
passage 10 of MSC culture.
Culture of Human Wharton’s Jelly Derived Mesenchymal
Stem Cells
Human umbilical cords were obtained from full term women
immediately after delivery from gynecology department of Manipal
hospital, Bangalore, India. Informed written consent was obtained
after getting an approval (Protocol No: MIRM/001/08) from
Institutional Ethics committee of Manipal Hospital and Manipal
Heart Foundation, Bangalore, India. After thorough washing with
DPBS containing antibiotics the cord was cut open and the arteries
and veins were removed. The tissue was treated with Collagenease
blend (Sigma, St.Louie, USA) at a net concentration of 500 mg/ml
for 20 hr. Post-digestion with collagenease the cells were filtered
through a 100 m cell strainer (BD FALCON, Bedford, USA) to
remove tissue debris. Cells were then washed with DPBS and
cultured in KO-DMEM containing 10% FBS, 2 mM L-Glutamine
andantibiotics.WJSCsweregrown tillconfluence andcellsbetween
Passage 3- Passage 8 were used for setting experiments after
characterizing for mesenchymal stem cell markers (Figure S1A).
Peripheral Blood Mononuclear Cells (PBMC) Culture and
Stimulation
Blood for PBMC culture and stimulation was obtained from
healthy donors after taking written consent using a protocol
(Protocol no. MIRM/ASC-2/08) approved by Institutional Ethics
committee of Manipal Institute of Regenerative Medicine,
Manipal University, Bangalore. PBMCs were separated from
heparinized blood of donors using Lymphoprep
TM. PBMCs
(1610
6 cells/ml) were cultured in 96 well plates (BD FALCON,
NJ,USA) in RPMI-1640 (GIBCO-BLR,USA)supplemented with
2 mM glutamine, 10% FBS and antibiotic-anti-mycotic. For
mitogenic stimulation experiments, PBMCs were treated with
Phytohaemagglutinin (PHA) (Biological Industries, Israel) at a
concentration of 20 mg/ml for different time intervals (12 to
96 hr).
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plates by co-culturing the responder PBMCs (1610
6 cells/ml) with
stimulator PBMCs (0.5610
6 cells/ml) from different donors or an
autologous control for 6 days in RPMI-1640 medium with 10%
FBS and antibiotics as described above. The stimulator PBMCs
were treated with 10 mg/ml mitomycin C (Sigma, St.Louie, USA)
for 2 hr and were thoroughly washed with DPBS before using them
for Mixed Lymphocyte Reaction (MLR) assay. Cell Proliferation
resulting from both mitogenic and allogenic stimulation of PBMCs
was measured by a BrdU cell proliferation assay kit (Calbiochem,
USA).
MSC Priming
Bone marrow derived MSCs and Wharton’s jelly derived MSCs
were primed with inflammatory cytokines 150 U/ml of IFNc
(Sigma, St.Louie, USA) and 10 ng/ml of TNFa (Sigma, St.Louie,
USA) for 72 hrs and subsequently analyzed for cell surface
markers. The dosage for IFNc and TNFa treatment of MSCs was
decided based on published reports [39,40,41]. Optimal time of
induction was chosen based on kinetic analysis of HLA-ABC and
HLA-DR surface expression (Figure S2). Primed and unprimed
MSCs were thoroughly washed after stimulation, either mitomycin
C treated (10 mg/ml) or untreated, and used for co-culture with
PBMCs in lymphoproliferation experiments. The dosage of
Mitomycin C used was affective in causing growth arrest of MSCs
(Figure S3).
Tri-Lineage Differentiation
BMMSC and WJMSC cells primed/unprimed with IFNc or
TNFa (72 hr) were washed with DPBS and cultured in adipogenic,
osteogenic or chondrogenic inductive media (media change was
done every 3 days) to evaluate their mesenchymal differentiation
potential.
Adipogenic inductive media contained 1.0 mM dexamethasone
(Sigma Aldrich), 0.5 mM isobutylmethylxanthine (Sigma Aldrich),
1.0 mg/ml insulin (Sigma Aldrich) and 100 mM indomethacin
(Sigma Aldrich) in DMEM-KO supplemented with 10% FBS. Oil
deposition in differentiated adipocytes was evaluated by Oil O
Red staining after 18 days.
Osteogenic inductive media contained 10
28 dexamethasone
(Sigma Aldrich), 50 mg/ml ascorbic acid (Sigma Aldrich), 10 mM
b-glycerophosphate (Sigma Aldrich) in DMEM KO supplemented
with 10% FBS. Mineralization was detected by Von Kossa
staining after 18 days.
Chondrogenic differentiation was induced in confluent mono-
layer cultures using chondrogenic differentiation media from
Lonza, Basal, Switzerland. Proteoglycan deposition was checked
by Safranin O staining after 15 days of induction [42].
Differentiation pictures depicted in Figure 1 are from MSCs at
Passage 5.
Additionally, Immuno-fluorescence staining was performed
with FABP-4, Osteocalcin and Collagen II specific antibodies to
ascertain adipogenic, osteogenic and chondrogenic differentiation
of MSCs respectively, post induction with differentiation media.
Immuno-Cytochemistry
MSCs were cultured and primed with IFNc/TNFa in BD
FALCON chamber slides. Post priming MSCs were induced with
specific differentiation media for either 15 or 18 days according to
protocols mentioned above. Subsequently, cells were fixed with
4% para-formaldehyde (Sigma) containing 5% Sucrose for 20
minutes at room temperature and washed twice with DPBS. Cells
were permeablized and blocked with 0.1% Triton X-100
containing 3% BSA in DPBS for 30 min. Staining with specific
primary antibodies was performed in DPBS containing 0.1% BSA
overnight at 4 degrees. Primary antibody staining was detected
using appropriate FITC conjugated secondary antibodies diluted in
DPBS containing 0.01% BSA. Cells were incubated in secondary
antibody for 45 minutes at room temperature. Cells were finally
washedthricewith0.01%Tween20containing0.1%BSAinDPBS
and counterstained with 4’, 6’-diamidino-2-phenylindole dihydro-
chloride (DAPI) for 5 minutes. Fluorescent images were captured
using a Nikon Eclipse 80i (Nikon) microscope and analyzed using Q
imaging software.
Figure 1. Phenotypic changes and tri-lineage differentiation
potential of human MSCs on exposure to IFNc and TNFa. (A)
Phase contrast pictures of MSCs, captured by a Nikon Eclipse TE2000S
microscope (magnification 10610), depicting phenotypic changes on
exposure to pro-inflammatory cytokines. (B) Lipid droplets stained with
Oil O Red depicting adipogenesis {Inset: FABP4 staining of MSC- derived
adipocytes} (magnification 20610) (C) Osteogenisis depicted by Von
Kossa staining of calcium mineralized deposits {Inset: Osteocalcin
staining of MSC derived mature osteocytes} (magnification 10610). (D).
Sulfated proteoglycans stained with Safranin O demonstrating chon-
drogenesis {Inset: Collagen II staining of MSC derived chondrocytes}
(magnification 10610). Control refers to cells unexposed to pro-
inflammatory cytokines.
doi:10.1371/journal.pone.0009016.g001
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Population doublings for each passage was calculated after the
cells reached 90% confluence using the formula lgNt–lgN0/lg2
[43]. Nt is the harvested cell number and N0 is the initial no. of
cells seeded at each passage. The mean cell no. was calculated by
trypan blue exclusion method (Figure S4).
Cytogenetics
The cytogenetic stability of BMMSCs and WJMSCs was
evaluated at passage 5 of culture with and without priming with
inflammatory cytokines by an independent diagnostic centre (Anand
diagnostics, Bangalore, India). 20 metaphases were screened and
analyzed by GTG banding.
MSC-PBMC Co-Cultures
Human bone marrow derived MSCs and Wharton’s jelly
derived MSCs, mitomycin C treated, were co-cultured with donor
PBMCs at ratios of 1:10 and 1:100 (MSC: PBMC ratio) (referred
to as 1% and 10% MSCs respectively in the tables and figures).
Proliferation rates were measured after 80 hr by BrdU cell assay
kit (Calbiochem) as per the kit protocol. Similar co-cultures were
set up even with MSCs primed by IFNc and TNFa. MSCs alone
and PBMCs alone were used as controls.
To check whether MSCs (primed/unprimed) influenced the
PBMC proliferation status, allogenic stimulation or mitogenic
stimulation of PBMCs was performed in presence of MSCs. MSCs
were allowed to adhere in the 96 well plates for 30 minutes before
addition of PBMCs along with PHA (mitogenic stimulation) or
mitomycin C treated stimulator PBMCs (in case of MLRs). The
proliferation was checked using BrdU incorporation as mentioned
above. Proliferation was measured after 80 hr in case of mitogenic
stimulation experiments and for 6 days in case of MLRs. The fold
suppression depicted in the tables was relative to PHA treated
PBMCs or PBMCs treated with stimulator PBMCS which was
considered as 100.
Culture supernatants were collected after different time intervals
in co-culture experiments set up in 96 well culture plates and
PBMCs were collected at the same time points mechanically for
cell surface analysis using flow cytometry. MSCs at passage 6 were
used for this set of experiments.
Cytokine ELISAs
Supernatants from mitogen stimulated cultures were collected
after different time intervals and stored at 220 degrees and the
samples were subsequently assayed in triplicates for specific
cytokines using respective cytokine kits (OptEIA Human ELISA;
BD Biosciences, CA, USA) according to manufacturer’s instruc-
tions. Optical Density (OD) was measured at 450 nm in the
Multilabel counter (VICTOR3
TM Multilabel Counter model
1420–032, Perkin Elmer).
For analysis of HGF and PGE2 levels supernatants were
obtained from control and primed MSC cultures after 72 hr.
Secreted levels of HGF and PGE2 was quantified using cytokine
ELISA kits from R&D Systems according to the kit protocols.
Real Time RT-PCR Analysis
Total RNA from BMMSCs and WJMSCs was isolated using
TRIzol (Invitrogen) and cDNA was synthesized using SuperScript
III First- Strand kit (Invitrogen). Real time RT-PCR analysis was
performed using Platinum SYBR Green qPCR SuperMix-UDG
kit (Invitrogen). All the above methods were executed according to
the manufacturer’s instructions. Real time analysis of IDO, HGF,
Cyclooxygenase-2 (COX2), Class II trans-activator (CIITA) and
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was done in
duplicates on an ABI 7500 Real-time PCR system (Applied
Biosystems). Reactions were set at 50uC for 2 minutes, 95uC for 10
minutes followed by 40 cycles of 95uC for 15 sec and the specific
annealing temperatures (refer Table S1) for 1 minute. A
dissociation step was incorporated for all analysis. SDS v1.4
software was used to analyze the results. Average CT was
calculated for different genes. DCT values depicted in the table
were calculated by subtracting the CT of test from CT of
endogenous control (GAPDH). Cycle threshold above 35.0 were
not considered for the analysis.
IDO Activity Assay
IDO catalyses the conversion of Tryptophan to N-Formyl
Kynurenine, which is catabolised to Kynurenine. Kynurenine
levels in the supernatants are directly proportional to IDO activity.
Culture supernatants from BMMSC and WJMSCs untreated or
treated with IFNc or TNFa were freshly harvested after 72 hr of
priming and conversion to Kynurenine was evaluated. 100 mlo f
culture supernatants were treated with 50 ml of 30% trichlor-
oacetic acid (Sigma Aldrich), vortexed and the tubes were
centrifuged at 930 g for 5 min, the supernatant obtained were
transferred to 96well plate followed by addition of equal volume of
Ehrlich reagent (Sigma Aldrich) (1% p-dimethylbenzaldehyde in
glacial acetic acid). OD was measured at 490 nm in Multilabel
counter (VICTOR
3TM Multilabel Counter model 1420–032,
Perkin Elmer). The amount of Kynurenine was determined using
a standard curve of Kynurenine (0–2500 mM) [44].
Flow Cytometry
Cell surface markers on MSCs were analyzed using a panel of
antibodies as mentioned above. Non-specific florescence was deter-
mined with appropriate isotype controls. PHA activated PBMCs
alone (indicated as ‘P+P’ in the figures) and PHA activated PBMCs
co-cultured with primed/unprimed MSCs (indicated by ‘+’ and
the co-culture condition in the figures) were washed with PBS and
stained in antibody containing buffer (DPBS containing 1% FBS
and 0.01% sodium azide) on ice for 45 minutes. For indirect
staining cells were washed and treated with appropriate secondary
antibody for 30 minutes on ice. Stained cells were subsequently
washed and fixed with 1% PFA and acquired on a BD LSR II flow
cytometer and the data was analyzed using the WinMDI software
(Figure 2).
Statistical Analysis
Results are represented as means 6 Standard deviation.
Student’s t-test was used to make statistical comparisons. p-value
of less than 0.05 (*) and less than 0.01(**) were considered to be
statistically significant.
Results
Stromal Cells Isolated from Human Bone Marrow and
Wharton’s Jelly Exhibit Conserved Mesenchymal
Characteristics
Although isolation procedures for BMMSC and WJMSCs differ
the conventional Mesenchymal characteristics, reported, like cell
surface marker expression or the mesenchymal lineage differentia-
tion capacity remains conserved. Both MSCs were positive for
CD73, CD90, CD105, CD166 and negative for CD34, CD45,
CD19 and HLA-DR (Figure 2, Figure S1). Interestingly smaller oil
droplets were observed in WJMSC derived adipocytes as compared
to adipocytes derived from BMMSCs (Figure 1, Figure S1B).
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Inflammatory Stimuli
Changes in morphology of BMMSCs were observed on addition
of pro-inflammatory cytokines, IFNc and TNFa. IFNc primed
BMMSCs looked bigger in size, had high amount of cytoplasm and
a flattened irregular shape. Whereas, TNFa primed cells appeared
more spindle shaped as compared to the control untreated
BMMSCs. However, WJMSCs did not show marked morpholog-
ical changes on treatment with pro-inflammatory cytokines
consistently (Figure 1A). IFNc is known to cause growth suppression
in several cell types (Chan KW et al., 2008). Thus, the proliferation
potential was checked in primed and unprimed MSCs at different
passages. An increase in population doublings of TNFa primed
BMMSCs was observed whereas IFNc priming decreased the
proliferative potential of BMMSCs only (Figure S4).
Despite changes in morphology the differentiation capacity of
BMMSCs and WJMSCs to mesenchymal lineages was not
compromised upon exposure to IFNc and TNFa. (Figure 1B, C,
D). No chromosomal abnormalities were observed in primed and
unprimed cells (Figure S5). MSCs primed with inflammatory
cytokines, IFNc and TNFa, exhibited a normal karyotype
suggesting cytogenetic stability of the cells.
MSCs from bone marrow and Wharton’s jelly were then
compared for different immunologically relevant markers upon
treatment with IFNc and TNFa Both the MSCs studied expressed
stem cell markers CD73 and SSEA4 and their expression was not
altered on treatment with IFNc or TNFa. BMMSCs and WJMSCs
express low levels of MHC class I but lack expression of HLA-DR
and co-stimulatory ligands, CD80 and CD86. Expression of other
crucial immune-stimulatory ligands; CD54 and CD50, and FAS
(CD95) were also analyzed. BMMSCs and WJMSCs express
significant levels of immune-adhesive ligand CD54 on their surface
which was induced greatly by IFNc and TNFa (Figure 2A and B).
However, CD95 and CD50 were not detected on MSCs even upon
treatment with inflammatory stimuli. The expression of stem cell
markers, CD73 and SSEA4 does not change significantly on
treatment with either IFNc or TNFa with both the MSCs tested.
HLA-ABC was induced majorly (Figure 2A, B) on treatment with
Figure 2. Inflammatory cytokines affect the immune-phenotype of human MSCs derived from bone marrow and Wharton’s jelly.
BMMSC’s (A) and WJMSC’s (B) cultured with or without IFNc or TNFa for 72 hr were stained with appropriate conjugated antibodies and the surface
expression was monitored by flow cytometry. Grey filled histograms represent specific isotype controls. Data is representative of three experiments
performed with three independent donor MSCs.
doi:10.1371/journal.pone.0009016.g002
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upregulated onBMMSCs onlyontreatmentwith IFNcbutnotwith
TNFa. HLA-DR was not detected on WJMSCs upon treatment
with either IFNc or TNFa.
This suggests that although MSCs from different tissue sources
have more or less conserved immune properties minor differences
exist in how they respond to inflammation.
Immunogenicity of BMMSCs and WJMSCs Primed with
Inflammatory Stimuli
MSCs have been reported to exhibit low immunogenicity when
co-cultured with allogenic PBMCs [45,46]. However, the
immunogenicity of IFNc and specially TNFa treated MSCs has
not been extensively tested. The ability of allogenic WJMSCs and
BMMSCs to elicit PBMC proliferation was tested in one-way
MLRs with mitomycin C treated MSCs as stimulators. MSCs
were either primed or unprimed with IFNc or TNFa for the MLR
reaction. As indicated in Table 1 mild proliferation was observed
with BMMSCs treated or untreated with IFNc. WJMSCs did not
cause proliferation of allogenic PBMCs over and above the
autologous control PBMCs, except in case of TNFa primed
WJMSCs were mild proliferation was observed even at 1% cell
dosage (p-value ,0.05). Immunogenicity of MSCs seems to
depend on the dosage of MSCs which interact with PBMCS.
Similar results were obtained with different isolates of BMMSCs
and WJMSCs. Thus it appears that inflammation does not majorly
affect the allo-recognition of MSCs.
MSCs Derived from Bone Marrow and Wharton’s Jelly
Modulate Mitogen Induced Lymphoproliferative
Responses to Different Extents
WJMSCs and BMMSCs do respond to inflammatory stimuli
(Figure 1, 2) and inflammation might influence the immune-
modulatory capacity of MSCs. To check this possibility WJMSCs
and BMMSCs either primed or unprimed with IFNc or TNFa,
were washed thoroughly and co-cultured with PHA-treated
PBMCs at 10% or 1% dosage as described in material and
methods. MSCs treated and untreated with mitomycin C were
used, for co-culture; to replicate the in vivo scenario where we
expect proliferating MSCs to interact with immune cells.
BMMSCs caused a mild suppression of mitogen simulated
lympho-proliferation. IFNc primed BMMSCs as well as TNFa
primed BMMSCs were able to cause suppression even at 1% cell
dosage (Table 2) at least in 3 of the 4 donor samples studied.
However, significant suppression was not observed when mitomy-
cin C treated BMMSCs were used in the co-culture experiments
suggesting that the suppression caused was dependent on BMMSC
proliferation.
Table 1. BMMSCs and WJMSCs primed with inflammatory
stimuli mildly effect proliferation of allogenic PBMCs.
Conditions % proliferation 6 S.D
BMMSC (P5) WJMSC (P5)
Allogenic PBMCs 100.0 100.0
PBMCs alone 7.460.01 7.460.01
+10% Control MSCs 14.863.6 6.664.7
+1% Control MSCs 4.666.8 0.160.01
+10% IFNc treated MSCs 14.964.1 4.462.8
+1% IFNc treated MSCs 5.162.2 1.060.08
+10% TNFa treated MSCs 9.762.3 16.566.6
+1% TNFa treated MSCs 3.060.8 12.164.3
‘‘+’’ refers to co-culture of allogenic PBMCs with either 1% or 10% dosage of
primed or unprimed MSCs. Fold proliferation was calculated relative to
proliferation of PBMCs when cultured with stimulator allogenic PBMCs which
was considered to be 100. This experiment was performed with different
isolates of BMMSCs and WJMSCs and similar results were obtained. One such
experiment done in triplicates at passage 5 (P5) is depicted in the table.
* p- value ,0.05 for 1% control MSCs versus 1% TNFa treated MSCs.
doi:10.1371/journal.pone.0009016.t001
Table 2. Mitogen induced lymphoproliferation responses upon co-culture with Bone marrow derived MSCs (BMMSCs).
Fold Proliferation 6 Standard deviation
Co-culture conditions BMMSC1 (P5) BMMSC2 (P5) BMMSC3 (P6) BMMSC4 (P6)
+10% BMMSC’s 87.0262.84 85.65610.60 85.8560.78 84.3965.00
+1% BMMSC’s 97.0665.92 108.87612.71 87.7761.69 98.6769.61
+10% IFN-c Treated BMMSC’s 67.5063.96 77.63612.71 79.3462.08 78.0160.74
+1% IFN-c Treated BMMSC’s 84.7763.65 97.4366.60 70.5465.54 80.6961.06
+10% TNF-a Treated BMMSC’s 80.8162.15 73.2567.10 69.6262.36 82.2561.94
+1% TNF-a Treated BMMSC’s 83.6763.58 133.06610.29 72.5469.19 82.3061.77
+10% BMMSC’s# 103.0161.03 121.93621.61 81.0965.71 104.4866.88
+1% BMMSC’s# 113.8763.05 102.95612.61 83.6362.05 98.6161.33
+10% IFN-c Treated BMMSC’s# 87.1265.88 94.96617.76 80.5763.51 133.3363.80
+1% IFN-c Treated BMMSC’s# 115.3362.04 125.84613.39 86.2565.66 107.2961.59
+10%TNF-aTreated BMMSC’s# 101.8163.43 75.3666.83 74.5664.42 123.4166.01
+1% TNF-a Treated BMMSC’s# 114.2563.73 119.67614.09 76.4864.38 127.17614.21
P is the passage no of MSC used. ‘‘+’’ in the co-culture conditions indicates fold proliferation in conditions were PHA-treated PBMCs were co-cultured with the
Mitomycin treated# or untreated BMMSCs either unprimed or primed with IFNc or TNFa. Differently treated BMMSCs (as mentioned above) were co-cultured with PHA
stimulated PBMCs for 80 hrs and BrdU incorporation was measured subsequently. Fold Proliferation was calculated with respect to the PHA treated PBMC control which
was considered to be 100. Each experiment with individual donors was performed in triplicates and the fold proliferation 6 S.D is depicted in the table. * p,0.05,
** p,0.01; 10% BMMSCs versus 10% IFNc treated BMMSCs *, 10% BMMSCs versus 10% TNFa treated BMMSCs *, 1% BMMSCs versus 1% IFNc treated BMMSCs **, 1%
WJMSCs versus 1% BMMSCs *.
doi:10.1371/journal.pone.0009016.t002
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lympho-proliferation responses to a greater extent then bone
marrow derived MSCs (Table 2, Table 3 and Table S2). In
contrast to BMMSCs, suppression of lymphoproliferation respons-
es were noticed even in 1% WJMSC co-cultures (p- value ,0.05
was obtained when co-cultures of BMMSCs and WJMSCs were
compared). IFNc or TNFa primed WJMSCs did not further
enhance the suppressive responses drastically as compared to the
untreated WJMSC. However, the suppression again seemed to be
dependent on the proliferative status of WJMSCs. Thus it looks
like priming with inflammatory stimuli can enhance the ability of
only BMMSCs and not WJMSCs to suppress mitogen induced
lymphoproliferation.
BMMSCs and WJMSCs Attenuate Allogenic Mixed
Lymphocyte Responses to Different Extents
Different doses of primed or unprimed MSCs were added to
MLRs containing PBMCs as responders and mitomycin treated
allogenic PBMCs as stimulators. This mimics the in vivo GVHD
reaction where MSCs are used as third party cells. BrdU
incorporation was measured after 6 days. 10% unprimed or
primed BMMSCs exhibited comparable suppression on MLRs.
Lower dosage (1%) of primed and unprimed BMMSCs in the
cultures resulted in an increase of proliferation in few of the
samples tested (Table 4).
Drastic suppression of MLR responses was observed with
WJMSCs as compared to BMMSCs (p-value 0.01). As compared
to BMMSCs the suppressive effect was seen even at 1% dose ratio
of primed and unprimed WJMSCs. Suppression was significantly
more when 10% IFNc treated cells were added to the MLRs
(Table 5) suggesting that probably IFNc treated WJMSCs
are more potent immune-modulators of allogenic responses
(p,0.01).
Cytokine Secretion Profiles of Activated PBMCs in
Co-Cultures with Primed MSCs
To analyzewhether MSCs affectthecytokine secretionprofilesof
activated lymphocytes WJMSCs and BMMSCs were co-cultured
Table 3. Mitogen induced lymphoproliferation responses upon co-culture with Wharton’s jelly derived MSCs (WJMSCs).
Fold Proliferation 6 Standard deviation
Co-culture conditions WJMSC 1 (P3) WJMSC2(P4) WJMSC3(P5) WJMSC4(P6)
+10% WJMSC’s 97.7668.52 51.38610.20 55.062.2 50.9360.64
+1% WJMSC’s 84.0069.58 49.76 61.34 84.466.9 50.2762.88
+10% IFN-c Treated WJMSC’s 62.0560.38 37.05616.78 54.063.8 63.3862.65
+1% IFN-c Treated WJMSC’s 70.19 63.63 49.76611.84 58.167.6 54.9461.94
+10% TNF-a Treated WJMSC’s 63.7964.92 61.2767.29 57.465.9 58.7966.05
+1% TNF-a Treated WJMSC’s 77.0660.1 95.3966.66 58.964.3 53.2460.73
+10% WJMSC’s# 94.3065.43 113.86622.70 82.1615.5 67.4467.55
+1% WJMSC’s# 87.57612.27 102.13616.56 94.963.1 81.9165.48
+10% IFN-c Treated WJMSC’s# 64.4060.23 121.85632.05 72.962.2 69.2765.79
+1% IFN-c Treated WJMSC’s# 86.5360.62 124.05649.30 102.563.6 78.8263.39
10% TNF-a Treated WJMSC’s# 90.3564.62 100.05613.66 79.663.6 68.0362.73
1% TNF-a Treated WJMSC’s# 80.7265.40 126.9769.49 105.465.7 79.5661.67
P is the passage no of MSC used. ‘‘+’’ in the co-culture conditions indicates fold proliferation in conditions were PHA-treated PBMCs were co-cultured with the
Mitomycin treated# or untreated WJMSCs either unprimed or primed with IFNc or TNFa. Differently treated WJMSCs (as mentioned above) were co-cultured with PHA
stimulated PBMCs for 80 hrs and BrdU incorporation was measured subsequently. Fold Proliferation was calculated with respect to the PHA treated PBMC control which
was considered to be 100. Each experiment with individual donors was performed in triplicates and the fold proliferation 6 S.D is depicted in the table. * p,0.05, 1%
WJMSCs versus 1% BMMSCs.
doi:10.1371/journal.pone.0009016.t003
Table 4. Effect of BMMSCs on MLR responses.
Fold Proliferation 6 Standard deviation
Co-culture conditions BMMSC1 (P5) BMMSC2 (P5) BMMSC3 (P6) BMMSC4 (P6)
+10% BMMSC’s 50.7365.6 64.58615.28 82.7663.58 73.5466.97
+1% BMMSC’s 95.0066.6 170.36629.02 115.3563.87 105.8364.27
+10% IFN-c Treated BMMSC’s 57.8665.97 70.75638.85 73.3265.83 68.5765.64
+1% IFN-c Treated BMMSC’s 80.11613.25 198.01618.46 108.5662.11 75.9867.01
10% TNF-a Treated BMMSC’s 43.6969.58 58.6665.50 79.0960.45 85.0968.65
1% TNF-a Treated BMMSC’s 94.20611.66 268.27614.45 112.3562.87 84.6863.93
P is the passage no of BMMSC used. BMMSCs treated or untreated with IFNc or TNFa were co-cultured with mismatched responder and stimulator PBMCs and the
allogenic response generated was measured by BrdU incorporation after 6 days in culture. Each experiment was performed in triplicates. Fold proliferation was
calculated relative to proliferation rates of responder PBMCs in the absence of MSCs which was considered to be 100. * p,0.05, 10% WJMSCs versus 10% BMMSCs.
doi:10.1371/journal.pone.0009016.t004
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supernatants were collected. Supernatants were evaluated for key
immune-modulating cytokines. BMMSCs and WJMSCs resulted in
reduction in secreted levels of IFNc in a dose dependent manner in
activated PBMC cultures (Figure 3). Primed BMMSCs caused a
greater reduction in IFNc than untreated BMMSCs (p,0.01). Co-
cultures with BMMSCs resulted in a minor increase in IL-10 levels
as compared to the control samples. However, a significant increase
in IL-10 levels was observed in co-cultures with either IFNc or
TNFa primed BMMSCs consistent with higher reduction in IFNc
levels(p,0.05).Only a marginal increase inIL-10 levels wasnoticed
with WJMSC at earlier time points.
A peak in IL-2 levels was observed in PHA stimulated
lymphocytes at 48 hr. BMMSCs changed the IL-2 kinetics and
secretion levels of activated lymphocytes. A consistent decrease in
IL-2 was observed beyond 24 hr as compared to the control PHA
activated PBMC cultures. WJMSCs did not cause a significant
change in the kinetics and threshold levels of IL-2 as compared to
the control samples except for the TNF a primed WJMSC co-
cultures were higher threshold levels of IL-2 were observed at all
the time points studied. Consistently IL-2SR levels increased
beyond 48 hr in the PHA activated control samples. Secreted
levels of IL-2SR were marginally more in BMMSC co-cultures
and WJMSC co-cultures than the control samples at all the earlier
time points studied (Figure 3 and Table S3).
No significant change in the secretion levels and kinetics of IL-
1b and IL-6 (data not shown) was noticed with either BMMSC or
WJMSC co-cultures.
IFNc produced by lymphocytes can act as a crucial signal for
release of TNFa by activated macrophages. Evaluation of TNFa
secretionprofiles inthe co-culture conditionsindicateda decrease in
the secreted levels with both BMMSCs and WJMSCs consistent
with the decrease in IFNc levels. Thus in a nutshell, WJMSCs and
BMMSCs might modify the immune response by inhibiting the
secretion of pro-inflammatory cytokines and increasing the levels of
suppressive cytokines like IL-10. Importantly, enhanced reduction
inpro-inflammatorycytokineslikeIFNcand TNFa uponco-culture
with primed BMMSCs could explain the increase in suppression of
PHA-induced lymphoproliferation in co-cultures with primed
BMMSCs.
Activation Marker Profile on Stimulated Lymphocytes Is
Altered by WJMSCs and BMMSCs Differently
MSCs affect the cytokine secretion profiles in mitogen
stimulated PBMC cultures. Further, the expression of activation
markers on mitogen stimulated PBMCs was evaluated upon co-
culture with either primed or unprimed MSCs. Only markers
which were obviously altered upon co-culture with MSCs are
depicted in Figure 4. The percent positive expression of all
the markers studied is depicted in Table 6 and Table 7 in
detail.
CD69, an early activation marker on T cells, was not changed
upon co-culture with BMMSCs and WJMSCs except for TNFa
primed BMMSC and WJMSCs where a reduction in surface levels
was observed.
CD28, a positive co-stimulatory ligand on T lymphocytes, was
diminished on co-culture with both 10% IFNc and 10% TNFa
primed BMMSCs. Surprisingly, at earlier time points co-culture
with 1% IFNc primed BMMSCs resulted in a sub-population of
CD28 high lymphocytes which was not sustained at later time
points (Figure 4A). CD28 levels do not seem to be modulated by
WJMSCs.
Co-culture with WJMSCs results in a substantial change in the
kinetics (expression was seen as early as 12 hr of activation) and
expression levels of the negative co-stimulatory ligand, CTLA4 on
PBMCs (Figure 4B {ii}). A very mild increase in CTLA4 was
observed with BMMSCs but the effect was not as striking as in the
case of WJMSCs (Figure 4B {i}). A decrease in MHC class I
expression was observed upon co-culture with 10% BMMSCs
either primed or unprimed (Figure 4C). The decrease was not so
evident with WJMSC co-cultures.
CD45RA and CD45RO markers are used to identify naı ¨ve
and memory T cell responses depending on their relative
expression levels [47]. Co-culture with BMMSCs results in a
transient up regulation of CD45RO levels at 24 hr with
1% BMMSCs and with IFNc primed BMMSCs at both the
doses tested (subpopulations of high CD45RO expression were
observed, Figure 4D). CD45RO expression pattern did not
change much upon WJMSC co-culture. However, no definitive
conclusions could be drawn from alterations in CD45RA expre-
ssion data.
No significant changes in the levels of CD4, CD8, CD95 was
observed in the co-culture conditions tested. Annexin V staining
was not detected on the activated PBMCs probably suggesting that
PBMCs are not undergoing apoptosis on co-culture with either
WJMSCs or BMMSCs (data not shown).
BMMSCs and WJMSCs could probably influence lymphopro-
liferation responses uniquely by differentially modulating the levels
of key immune activation markers which contribute to the
development of the immune response.
Table 5. Effect of WJMSCs on MLR responses.
Fold Proliferation 6 Standard deviation
Co-culture conditions WJMSC1(P4) WJMSC2(P5) WJMSC3(P6) WJMSC (P4)
+10% WJMSC’s 47.48610.39 21.0614.0 32.0568.36 42.10612.33
+1% WJMSC’s 78.36624.07 92.769.8 60.0865.57 54.6663.21
+10% IFN-c Treated WJMSC’s 29.7864.22 16.461.1 10.3164.46 26.6268.08
+1% IFN-c Treated WJMSC’s 81.7866.55 103.262.0 69.9862.44 51.64612.24
10% TNF-a Treated WJMSC’s 53.57616.23 31.3627.0 28.6162.03 42.6066.42
1% TNF-a Treated WJMSC’s 60.2967.72 48.863.6 56.5963.64 40.9060.95
P is the passage no of WJMSC used. WJMSCs treated or untreated with IFNc or TNFa were co-cultured with mismatched responder and stimulator PBMCs and the
allogenic response generated was measured by BrdU incorporation after 6 days in culture. Each experiment was performed in triplicates. Fold proliferation was
calculated relative to proliferation rates of responder PBMCs in the absence of MSCs which was considered to be 100. * p,0.05, 10% WJMSCs versus 10% BMMSCs,
** p,0.01, 10% WJMSCs versus 10% IFNc treated WJMSCs.
doi:10.1371/journal.pone.0009016.t005
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PLoS ONE | www.plosone.org 8 February 2010 | Volume 5 | Issue 2 | e9016Figure 3. Cytokine secretions from activated lymphocytes are differentially altered upon co-culture with BMMSCs and WJMSCs. The
graphs represent amounts of cytokine released (y axis) from MSC/PHA-activated PBMC co-cultures at different time points of activation (x axis). Panel
A and Panel B refers to cytokine secretions in BMMSC and WJMSC co-cultures respectively.
doi:10.1371/journal.pone.0009016.g003
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Expressed by BMMSCs and WJMSCs
To explore the reason behind the mechanistic differences in
immune-modulation observed quantitative RT-PCR analysis was
performed to screen for differences in expression of known
immune-suppressive factors in primed/unprimed MSCs. Differ-
ences in mRNA expression of IDO, HGF, COX2 and CIITA was
consistently observed (Figure 5A). Based on the PCR screen IDO
enzyme activity levels and secretion levels of HGF and COX2
generated PGE2 was evaluated in supernatants of primed/
unprimed MSCs.
IDO is an IFNc inducible enzyme which depletes Tryptophan
and thus inhibits T cell proliferation [48]. IDO has not been
shown to be expressed by MSCs but is inducible by IFNc. [49].
IFNc inducible IDO activity was higher in IFNc primed
BMMSCs than IFNc primed WJMSCs (Figure 5B).
Figure 4. Expression of key activation markers on PHA-stimulated lymphocytes were differentially altered upon co-culture with
primed BMMSCs and WJMSCs. Flow cytometry analysis of CD28 (4A), CTLA4 (4B {i}, 2B {ii}), HLA-ABC (4C) and CD45RO (4D) on PHA-treated PBMCs
was performed kinetically during different co-culture conditions. ‘‘P+P’’ is PBMC stimulated with PHA and ‘‘+’’ refers to activation markers on PHA-
stimulated PBMCs when co-cultured with primed or unprimed MSCs. Key changes are highlighted. % positive cells depicted within each histogram
are calculated using FACSDiva software.
doi:10.1371/journal.pone.0009016.g004
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was induced only in IFNc primed MSCs consistent with the
lack of HLA-DR expression in control and TNFa primed MSCs
(Figure 2). Lower transcript levels of CIITA was detected in
IFNc primed WJMSCs than BMMSCs. HLA-DR cell surface
expression was not detected on IFNc primed WJMSCs despite
the presence of CIITA suggesting a probable regulation at
protein levels or very late activation kinetics as previously
described [41].
Similarly, BMMSCs secreted higher levels of PGE2 than
WJMSCs (Figure 5B). Although TNFa has been shown to
induce BMMSC secreted PGE2 in our hands the TNFa induction
was not so robust [8]. However, WJMSC secreted PGE2 was
induced upon priming with IFNc and more particularly with
TNFa.
A drastic difference in HGF secretion as well as transcript levels
was observed in both the MSCs (Figure 5A, B). TNFa priming of
WJMSCs resulted in marked reduction of HGF secretion.
Taken together the present data emphasizes differences in
immune-suppressive factors between BMMSCs and WJMSCs and
their induction with pro-inflammatory cytokines.
Discussion
Bone marrow and Wharton’s jelly derived MSCs were
evaluated for expression of immunologically relevant ligands upon
treatment with IFNc and TNFa. Both BMMSCs and WJMSCs
seemed to have a hypo-immune profile, as evidenced by lack of co-
stimulatory ligands, CD80/CD86 and CD50 even on pretreat-
ment with IFNc and TNFa. HLA-ABC and immuno-adhesive
ligand, CD54 was greatly induced by IFNc and TNFa. HLA-DR
was induced only in BMMSCs on IFNc treatment and not so in
WJMSCs (Figure 2). Although HLA-DR has been reported to be
greatly induced by IFNc in both WJMSCs [50] and BMMSCs
[46] HLA-DR was only mildly induced in WJMSCs as compared
to BMMSCs in our hands. It’s possible that WJMSCs and
BMMSCs respond to different thresholds of inflammation.
Although induction of MHC class I and Class II was observed
on IFNc treatment, no co-stimulatory molecules were detected,
suggesting a tolerogenic phenotype even under inflammatory
conditions [46]. Our observations are in coherence with these
results. In addition we suggest that probably minor differences do
exist in the way different MSCs respond to different kinds and
Table 6. Co-culture with BMMSCs derived from bone marrow result in changes in expression patterns of key immune activation
markers on stimulated lymphocytes.
12 h 24 h 48 h 72 h 96 h 12 h 24 h 48 h 72 h 96 h
CD69 HLA-ABC
P+P 1.5 12.2 23.8 28.6 12.5 P+P 3.0 3.6 10.4 17.6 28.2
+10%C 2.1 11.6 21.2 21.8 5.9 +10% C 1.3 4.3 2.9 14.8 9.3
+1% C 6.6 0.0 23.5 21.8 6.4 +1% C 2.4 1.6 6.6 17.1 29.6
+10% I 2.8 9.4 19.7 18.0 11.4 +10% I 3.0 2.4 11.6 17.7 13.7
+1% I 6.7 11.0 18.1 12.5 5.7 +1% I 1.4 1.2 8.6 14.3 25.6
+10% T 6.2 15.0 14.1 16.0 4.9 +10% T 2.2 3.2 19.0 22.2 13.0
+1% T 2.6 11.6 17.4 14.0 13.8 +1% T 0.5 2.2 6.3 20.3 28.6
CD28 CD-45RO
P+P 6.5 19.2 21.9 34.9 10.4 P+P 10.8 18.6 16.5 25.1 16.3
+10% C 2.6 16.0 18.8 25.2 10.8 +10% C 5.9 8.8 15.3 22.4 6.9
+1% C 7.8 14.5 19.2 8.7 7.0 +1% C 3.9 36.1 17.1 26.1 21.0
+10% I 1.3 9.7 19.4 15.3 10.5 +10% I 9.2 30.7 17.5 27.8 16.4
+1% I 4.8 28.9 23.5 29.1 5.9 +1% I 8.8 35.5 21.5 18.8 17.7
+10% T 4.8 20.9 18.3 14.1 10.1 +10% T 5.1 13.9 16.9 17.3 18.6
+1% T 6.3 9.4 14.9 18.6 6.3 +1% T 14.5 9.6 23.0 18.3 20.7
CTLA4 CD-45RA
P+P 5.6 3.8 11.2 12.5 3.6 P+P 28.9 11.6 28.5 28.9 37.4
+10% C 11.9 13.1 7.4 10.2 6.1 +10% C 4.0 8.0 29.4 33.7 19.0
+1% C 7.6 13.1 14.8 12.9 4.1 +1% C 8.5 11.9 25.4 28.2 26.9
+10% I 7.8 4.8 13.3 9.5 6.0 +10% I 27.1 11.2 25.7 22.2 32.6
+1% I 11.2 12.0 15.1 13.0 3.7 +1% I 22.4 11.7 22.2 28.4 22.1
+10% T 6.6 10.3 6.8 6.9 0.2 +10% T 16.6 6.8 27.8 14.5 24.8
+1% T 7.2 8.8 13.6 14.2 5.1 +1% T 7.7 12.3 18.5 19.5 36.8
PBMCs were stimulated with PHA in the presence of different dosage of BMMSCs either untreated or treated with inflammatory stimuli IFNc (I) and TNFa (T) for different
time intervals. Subsequently PBMCs were picked and the surface expression of activated PBMCs under different co-culture conditions was monitored by Flow
cytometry. % positive cells expressing the specific marker are depicted in the table were obtained using FACSDiva software.
doi:10.1371/journal.pone.0009016.t006
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TNFa resulted in changes in the morphology and growth
characteristics of BMMSCs (Figure 1A, Figure S4). However,
markers reported to be present on mesenchymal cells SSEA4
and CD73 (Figure 2) did not change drastically on priming with
either IFNc or TNFa Differentiation capacity of MSCs to all
the three mesenchymal lineages was also not compromised after
priming (Figure 1B,C,D). Thus pretreatment with inflammatory
cytokines does not affect the ‘‘mesenchymalness’’ of WJMSCs and
BMMSCs.
There is lot of confusion in the literature regarding the
immunogenicity of MSCs in an allogenic platform [19,51,52].
MSCs do not express blood group antigens and no alloantibodies
were detected post MSC transplantation in allogenic Hematopoi-
etic stem cell transplantation (HSCT) recipients [53]. Weiss et al.,
2008 has shown that WJMSCs do not elicit allogenic as well as
Xenogenic responses in vitro [29]. However, intracardiac allogenic
porcine MSCs have shown to elicit an immune response
contradicting the in vitro data [54]. Porcine umbilical cord derived
stem cells did not induce a considerable immune response in vivo
but stimulation with IFNc or injection in an inflamed region
resulted in immunogenicity [50]. These discrepancies could be
partly due to heterogeneous MSC populations when isolated from
different tissues or the influence of environmental factors like
inflammation affecting the immunogenicity of MSCs. Thus the
immunogenicity of both WJMSCs and BMMSCs were evaluated
after priming with pro-inflammatory cytokines in a one way MLR
(Table 1). Although significantly high immunogenicity was not
observed in different pre-treatment conditions, TNFa treatment of
WJMSCs resulted in slight enhancement of immunogenicity
(Table 1) suggesting that different pro-inflammatory cytokines
can exert different effects in conferring immunogenicity to MSCs
depending upon the predominant cytokine at the site of
inflammation. Low dose MSCs seems to elicit a lower proliferative
response in PBMCs as compared to PBMC alone control within
the limitations of the assay sensitivity (Table 1). There is enough
evidence which now suggests that MSCs are not inherently
immune-evasive and the immune-privilege status is a flexible state
depending upon cell to cell interactions and importantly soluble
factors secreted by MSCs [35]. Fange et al., 2006 have elegantly
shown the importance of cells numbers in affecting allo-T cell
proliferation [55].The report clearly suggests that depending on
Table 7. Co-culture with WJMSCs derived from Wharton’s jelly result in changes in expression patterns of key immune activation
markers on stimulated lymphocytes.
12 h 24 h 48 h 72 h 96 h 12 h 24 h 48 h 72 h 96 h
CD69 HLA-ABC
P+P 24.5 24.4 5.0 1.6 2.9 P+P 26.7 27.4 21.3 32.3 46.7
+10%C 16.0 27.0 9.3 4.1 3.8 +10% C 30.0 26.1 22.1 32.7 36.8
+1% C 21.1 27.4 5.3 5.7 3.5 +1% C 32.0 27.6 22.7 38.2 53.4
+10% I 22.7 25.9 8.4 5.0 6.4 +10% I 32.2 36.5 23.4 40.9 39.6
+1% I 13.6 22.4 10.1 4.3 2.5 +1% I 32.1 30.5 32.6 31.8 46.6
+10% T 7.4 23.5 5.6 3.7 5.3 +10% T 37.6 29.8 34.4 37.1 41.6
+1% T 19.4 19.0 15.1 7.8 2.3 +1% T 29.9 26.0 28.9 24.8 46.9
CD28 CD-45RO
P+P 22.8 15.7 10.1 2.9 2.4 P+P 28.4 24.6 18.1 1.9 12.7
+10% C 15.5 16.9 8.3 5.9 4.7 +10% C 25.3 30.8 14.8 9.6 14.5
+1% C 18.4 24.1 9.7 6.0 4.2 +1% C 28.4 28.1 13.9 20.4 34.2
+10% I 14.6 18.6 8.1 6.9 6.3 +10% I 21.2 22.7 18.1 11.5 16.3
+1% I 23.1 18.9 8.4 5.0 3.0 +1% I 23.6 29.0 11.7 8.3 17.3
+10% T 18.5 16.1 10.6 8.9 3.4 +10% T 27.1 21.6 12.3 6.3 18.5
+1% T 32.4 20.8 8.0 4.6 1.8 +1% T 27.9 24.9 12.2 9.8 10.5
CTLA4 CD-45RA
P+P 9.0 14.7 6.9 8.9 6.4 P+P 34.7 34.5 36.4 9.0 15.3
+10% C 17.7 27.0 7.0 10.4 11.0 +10% C 26.6 37.1 26.6 24.5 19.4
+1% C 22.6 20.0 5.9 13.4 6.2 +1% C 41.8 41.8 25.3 20.4 13.6
+10% I 15.7 14.4 10.5 13.0 7.2 +10% I 29.1 35.0 38.9 16.1 17.1
+1% I 21.5 16.5 16.5 8.1 2.1 +1% I 38.1 42.7 35.4 12.9 14.7
+10% T 21.6 16.8 13.9 3.1 4.1 +10% T 28.3 39.0 35.2 20.9 15.0
+1% T 22.2 21.2 9.1 1.8 3.7 +1% T 30.1 29.5 35.7 12.6 26.2
PBMCs were stimulated with PHA in the presence of different dosage of WJMSCs either untreated or treated with inflammatory stimuli IFNc (I) and TNFa (T) for different
time intervals. Subsequently PBMCs were picked and the surface expression of activated PBMCs under different co-culture conditions was monitored by Flow
cytometry. % positive cells expressing the specific marker are depicted in the table were obtained using FACSDiva software.
doi:10.1371/journal.pone.0009016.t007
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potential of MSCs the balance can mildly shift towards either
higher suppression or low alloreactivity. Data depicted in Table 1
indicates only very mild allo-reactivity to MSCs (10% dosage) in
comparison to allogenic PBMCs which is considered as 100%. It’s
possible that at 1% dosage the suppressive mechanisms overrule
the mild allo-reactivity in our case.
WJMSCs and BMMSCs pretreated with IFNc and TNFa
modulated mitogen induced and allo-antigen induced lympho-
proliferation responses distinctly (Table 2, Table 3, Table 4, and
Table 5). WJMSCs were more suppressive than BMMSCs as
evident by suppression observed even at lower dosage. In addition,
inflammation seemed to enhance the capability of BMMSCs to
attenuate PHA induced lymphoproliferation but not of WJMSCs
(Table 2, Table 3 and Figure S6). WJMSCs attenuated MLR
reactions to a greater extent than BMMSCs (Table 4 and Table 5).
In comparison to mitogen-induced lymphoproliferation, BMMSCs
seemed to cause a more prominent suppression of MLR. Primed
BMMSCs are not better in suppressing MLRs than unprimed
BMMSCs. In contrast to BMMSCs, priming of WJMSCs by IFNc
seems to marginally enhance their capacity to attenuate MLRs. All
together, it appears that mitogen induced lymphoproliferation and
allo-antigen driven lymphoproliferation are modulated probably by
different mechanisms unique for BMMSCs and WJMSCs. In a
previous report it was shown that fetal human MSCs inhibit
proliferation to PHA and not to alloresponses in MLRs [32];
however these responses were not evaluated in comparison to
BMMSCs. The differences observed with PHA-induced and allo-
antigen driven lymphoproliferation responses in different conditions
might be due to the fact that in a polyclonal setting MSCs inhibit
activation of distinct T cells. In a more complex immune reaction
like a MLR, the immune-suppressive effect on both the PBMCs by
MSCs as well as the weak allogeneic response against the primed/
unprimed MSC must be considered. Even mild immunogenicity
conferred to MSCs upon priming could attribute to the differential
effects (Table 1). Thus exposure to inflammatory stimuli might even
influence the immune-regulatory behavior of WJMCS and
BMMSCs in a distinct fashion.
To understand the differences observed in the extent of
immune-suppression caused by BMMSCs and WJMSCs, we
probed into the cytokine secretion profiles of PHA-activated
lymphocytes in co-cultures with either primed or unprimed MSCs.
Both BMMSCs and WJMSCs reduce the production of pro-
inflammatory cytokines IFNc and TNFa (Figure 3 and Table S3).
However, the kinetics and threshold levels of pro-inflammatory
cytokine IL-2 was modulated only by BMMSCs and not with
WJMSCs except when primed with TNFa. BMMSCs but not
WJMSCs enhanced the levels of immune suppressive cytokine
IL-10. Taken together although both MSCs skew the cytokine
secretion profiles from a pro-inflammatory to an anti-inflamma-
tory phenotype, in depth analysis indicate differences in the type of
cytokines modulated by both the MSCs studied. The differences in
the cytokine profiles in lymphoproliferation reactions under
different co-culture conditions could account for the differences
in extent of immune-suppression observed with primed BMMSCs
and WJMSCs.
Lymphocyte proliferation is marked by characteristic signatures
of activation marker expression which eventually modulate the
Figure 5. Differences in immune-suppressive gene and protein levels in primed/unprimed BMMSC and WJMSCs. (A) Delta Cycle
Threshold (delta CT) is obtained after subtracting the endogenous control (GAPDH) Cycle Threshold from the test. ND refers to not detected. (B) IDO
activity (reflected by Kynurenine amounts), PGE2 and HGF levels are depicted.
doi:10.1371/journal.pone.0009016.g005
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proliferation as well as the time course of activation marker
expression would give a clearer insight into the mechanisms of
immune modulation [56]. Optimal T cell activation in vivo also
requires two signals, one being induced by MHC-TCR interaction
and the other provided by positive co-stimulatory ligands like
CD28. Eventually there is an up-regulation of negative co-
stimulatory ligands like CTLA4 which attenuate T cell responses.
High CTLA4 levels early on during an activation response have
been implicated in tolerance induction [57]. Both antigenic as well
as mitogenic stimuli initiate the transition from a CD45RA
phenotype to different transitional states of CD45RO positivity
and this response is finely tuned by cytokine milieu at the site of
inflammation [58].
To substantiate the previous experiments, changes were also
observed incell surfacemarkerprofile on mitogen activatedPBMCs
differentially upon co-culture with primed and unprimed WJMSCs
and BMMSCs (Figure 4, Table 6 and Table 7). Priming with either
TNFa or IFNc also caused differential modulation in the surface
expression of activated lymphocytes suggesting that these two
cytokines could possibly modulate the immune regulatory proper-
ties of MSCs differentially. Similar to our observations immune-
modulatory effects of murine BMMSCs have been reported
to be differentially modulated by IFNc and TNFa [40]. MSCs
could result in suppression by decreasing the levels of positive
co-stimulatory markers and increase in negative co-stimulatory
molecules on T cells resulting in an anergic state.
Consistent with enhanced suppression with pro-inflammatory
cytokine primed BMMSCs a decrease in levels of CD28 was
observed at 72 hr of activation (Figure 2A). In case of WJMSCs
although positive co-stimulatory ligands were not majorly
modulated in comparison to BMMSCs, the very early (12 hr of
activation response) and enhanced appearance of negative co-
stimulatory ligands like CTLA4 might have resulted in greater
suppression despite the presence of CD28 (Figure 4B {ii}). Further
a difference in the relative levels of CD45RA and CD45RO was
observed only upon co-culture with BMMSCs. Low amounts of
BMMSCs (1% dosage) and IFNc primed BMMSCs only caused
an increase in the CD45RO subset at 24 hr of activation
suggesting induction of memory like phenotype (Figure 4D) It is
possible that low levels of MSCs and priming could result in an
initial activation response which is not sustained later on. Current
reports in the field suggest that immune suppression by MSCs is
not inherent but is acquired upon interaction with immune cells
and their secretions [35]. It’s possible that MSCs are initially
detected by immune cells but later adopts mechanisms to evade
the response. Work is ongoing to evaluate in detail the lymphocyte
subsets which arise upon interaction with WJMSCs and
BMMSCs.
Changes in the activation marker profiles with primed MSCs at
different dosages indicate that the overall contribution of MSCs in
modulating the signal strength of a T cell response should carefully
be evaluated in context of other immune populations before
drawing definitive conclusions. Priming with inflammatory stimuli
changes the threshold levels of immune adhesive ligands like
CD54 (Figure 2) and might also change the cytokine secretion
profiles of MSCs which have immunological relevance. Differ-
ences in cytokine secretion profiles of BMMSCs and fetal MSCs
have been reported [31,59,60]. Both soluble and contact-
dependent mechanisms have been implicated in MSC immune-
modulation [8,33,60,61]. Immune-suppression studies with con-
ditioned media from BMMSCs as well as with culture inserts
emphasize on a major role of soluble factors in this phenome-
non [8]. Expression levels of known MSC immune-modulatory
molecules such as IDO, HGF and COX2 generated PGE2
differed in culture supernatants of both the MSCs (Figure 5).
Further these factors were differently modulated by inflammatory
stimuli thus suggesting the possibility that inflammation can fine
tune the immune properties of various tissue derived MSCs
distinctly. Further work is ongoing to definitively dissect out the
role of immunosuppressive molecules differentially expressed in
both the MSCs in lymphocyte/MSC co-cultures.
In a nutshell, this work emphasizes on the role of local
inflammatory factors in modulating the immune-regulatory
properties of two different MSCs. MSCs do respond to
inflammatory stimuli, taking part actively in an immune response
and cannot be just thought of as silent spectators. Lower dosage of
cells resulted in slight enhancement in the proliferation rate
especially in MLR reactions with BMMSCs (Table 4) and also
resulted in mild changes in the activation marker profile of PHA-
stimulated PBMCs. Importantly different activation markers and
cytokines were modulated by BMMSCs and WJMSCs under
different priming conditions. These results indicate that caution
should be taken while determining the dosage of MSCs and
understanding the pathophysiology of the disease before putting
them for therapeutic usage. A recent study by Magatti et al., 2008,
indicates the existence of cells with both immune suppression and
immune stimulation capabilities within amniotic mesenchymal
MSCs [62]. As an off shoot of this work it will be interesting to
investigate whether different subsets of MSCs having distinct
immune behaviors exist within the heterogeneous pool of MSCs in
different tissues. It is possible that these subsets respond differently
to inflammatory stimuli. In totality the present work pinpoints and
strengthens the recent evidences regarding the inherent differences
between MSCs differing in their primitiveness. Stromal cells from
different tissues have been shown to exhibit site-specific molecular
identity and memory [63]. However there is not enough evidence
in the literature which suggests that these affect the immune
properties of stromal MSCs. Observations discussed suggest that
inherent differences between different MSCs can impact the
mechanism and extent of immune-modulation exhibited probably
due to differences in immuno-suppressive factor expression and
secretion. The hallmark of this study is the identification of
putative mechanisms by which different MSCs cause immune-
modulation. This work emphasizes that effect of predominant
inflammatory cytokines at the site of transplantation should be
considered for accessing the immunogenicity and immune-
modulatory behavior of MSCs in different clinical settings.
Supporting Information
Table S1 List of primer sequences used for real-time RT-PCR
analysis.
Found at: doi:10.1371/journal.pone.0009016.s001 (0.03 MB
DOC)
Table S2 Mitogen induced lymphoproliferation responses upon
co-culture with bone marrow derived MSCs (BMMSCs) and
Wharton’s jelly derived MSCs (WJMSCs).
Found at: doi:10.1371/journal.pone.0009016.s002 (0.04 MB
DOC)
Table S3 MSCs from bone marrow (A) and Wharton’s jelly (B)
modulate the kinetics and secretion profiles of key cytokines in
lymphoproliferation experiments.
Found at: doi:10.1371/journal.pone.0009016.s003 (0.14 MB
DOC)
Figure S1 WJMSCs and BMMSCs exhibit conserved mesen-
chymal marker expression (A) and differentiation capacities (B, C).
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positivity for each marker is shown in the figure and isotype
control has been used for gating. ND-No positive population
detected. (B) Represents Oil O Red staining of adipocytes induced
from MSCs (magnification 10640). (C) Represents Von Kossa
staining of mineralized deposits after osteogenic induction of
MSCs (magnification 10610).
Found at: doi:10.1371/journal.pone.0009016.s004 (2.86 MB TIF)
Figure S2 Kinetics of expression of HLA-ABC and HLA-DR on
MSCs upon treatment with pro-inflammatory cytokines IFNc and
TNFa. BMMSCs (A) and WJMSCs (B) were treated or untreated
(black line) with 150 U/ml of IFNc or 10 ng/ml of TNFa for
either 24 hr (grey lines), 48 hr (black dotted lines) or 72 hr (thick
black line) and subsequently cell surface levels of HLA-ABC or
HLA-DR was evaluated by Flow cytometry. Grey filled histogram
represents staining with the matched isotype controls.
Found at: doi:10.1371/journal.pone.0009016.s005 (0.61 MB TIF)
Figure S3 BrdU uptake of MSCs treated with Mitomycin C
(10mg/ml) is comparable or lower than resting PBMCs in culture.
The grey filled histogram represents BMMSCs whereas black filled
histogram represents WJMSCs. RFU is relative fluorescence units
after subtraction from endogenous fluorescence controls (-BrdU
sample).
Found at: doi:10.1371/journal.pone.0009016.s006 (1.43 MB TIF)
Figure S4 Exposure to IFNc and TNFa alters the replication
potential of BMMSCs. PD refers to population doublings calculated
after priming with either IFNc or TNFa at each passage (P) as
indicated on the x-axis.
Found at: doi:10.1371/journal.pone.0009016.s007 (0.49 MB TIF)
Figure S5 Normal karyotype of unprimed and primed WJMSCs
and BMMSCs. Karyotype of Passage 5 MSCs is depicted.
Found at: doi:10.1371/journal.pone.0009016.s008 (0.73 MB TIF)
Figure S6 BMMSCs and WJMSCs retain their immuno-
modulatory properties on exposure to varying doses of pro-
inflammatory cytokines. C refers to proliferation in PHA treated
PBMCs. ‘‘+’’ refers to co-cultures of PHA treated PBMCs and
MSCs primed with different concentrations of IFNc or TNFa.
Representative experiment performed in triplicates is depicted
above.
Found at: doi:10.1371/journal.pone.0009016.s009 (0.61 MB TIF)
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